Combined drug for immunotherapy of malignant tumors

Abstract

The invention discloses a combined drug for immunotherapy of malignant tumors. The combined drug includes a preparation containing interleukin 2, and a preparation containing intestinal probiotics; the pharmacological studies confirm that the combined drug of the present invention has a function of reducing tumor burden and controlling tumor growth, can promote the infiltration of cytotoxic T cells and the differentiation and differentiation of dendritic cells, improve the tumor immune microenvironment, can make up for the deficiency of the interleukin 2 alone in the tumor immune microenvironment, and can be applied to the immunotherapy of various malignant tumors.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a combined drug for immunotherapy of malignant tumors. Background technique [0002] Malignant tumors have gradually become one of the major threats to human health. At present, traditional treatment methods mainly include surgical resection, radiotherapy, chemotherapy, tumor-targeted drugs, adoptive immunotherapy, and tumor vaccines. Traditional tumor therapy has shown a "ceiling effect". With the deepening of research on tumor immunology, cell biology and molecular technology, tumor immunotherapy has become a research hotspot in the past few years, opening up a new direction for tumor treatment. Tumor immunotherapy is a therapeutic method that enables the body to generate a tumor-specific immune response in an active or passive manner, restores or improves the activity of the body's immune system, and fully exerts its ability to inhibit and kill tumor cells. Tumor immunoth...

AI Technical Summary

Problems solved by technology

Chinese patent CN201480014872.1 discloses the targeted delivery of probiotics and / or therapeutic agents to the gastrointestinal tract, both of which use intestinal probiotics as carriers and traditional Chinese medicine or traditional Chinese medicine ingredients as active substances to achieve the purpose of treating tumors or anticancer However, the mechanism of action of traditional Chinese medicine is not yet clear, and the pertinence is not strong, and the function of intestinal probiotics may be inhibited when combined with traditional Chinese medicine as a carrier

Chinese patent CN00819253.7 discloses the application of drug combination drugs containing interleukin-2 in pharmaceuticals, and Chinese patent CN200410025249.4 discloses the fusion protein of tumor necrosis treatment monoclonal antibody-interleukin 2 and its preparation method and application. Patients are treated with interleukin 2 alone or with carrier protein fusion therapy. There are deficiencies in the use of interleukin 2 alone to act on the tumor immune microenvironment. Although the fusion protein can improve the curative effect, the cost is high and it is easy to appear incomplete. target protein, which increases the difficulty of obtaining and affects the function of the protein itself

Images